Patents by Inventor Chapman M. Wright

Chapman M. Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrug activation in cancer cells using molecular switches
    Patent number: 9469841
    Abstract: The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a prodrug activating enzyme and a protein that binds a cancer specific marker, polynucleotides encoding the polypeptides, and molecular switches for converting a prodrug into a toxin, comprising the polypeptides. The invention also features methods for converting a prodrug into a toxin, methods for treating cancer, and methods for making the molecular switches, as well as kits.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: October 18, 2016
    Assignee: The Johns Hopkins University
    Inventors: Marc A. Ostermeier, Chapman M. Wright
  • PRODRUG ACTIVATION IN CANCER CELLS USING MOLECULAR SWITCHES
    Publication number: 20140273217
    Abstract: The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a prodrug activating enzyme and a protein that binds a cancer specific marker, polynucleotides encoding the polypeptides, and molecular switches for converting a prodrug into a toxin, comprising the polypeptides. The invention also features methods for converting a prodrug into a toxin, methods for treating cancer, and methods for making the molecular switches, as well as kits.
    Type: Application
    Filed: May 30, 2014
    Publication date: September 18, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Marc A. Ostermeier, Chapman M. Wright
  • Prodrug activation in cancer cells using molecular switches
    Patent number: 8771679
    Abstract: The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a prodrug activating enzyme and a protein that binds a cancer specific marker, polynucleotides encoding the polypeptides, and molecular switches for converting a prodrug into a toxin, comprising the polypeptides. The invention also features methods for converting a prodrug into a toxin, methods for treating cancer, and methods for making the molecular switches, as well as kits.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: July 8, 2014
    Assignee: The John Hopkins University
    Inventors: Marc Alan Ostermeier, Chapman M. Wright
  • PRODRUG ACTIVATION IN CANCER CELLS USING MOLECULAR SWITCHES
    Publication number: 20110135620
    Abstract: The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a prodrug activating enzyme and a protein that binds a cancer specific marker, polynucleotides encoding the polypeptides, and molecular switches for converting a prodrug into a toxin, comprising the polypeptides. The invention also features methods for converting a prodrug into a toxin, methods for treating cancer, and methods for making the molecular switches, as well as kits.
    Type: Application
    Filed: August 13, 2009
    Publication date: June 9, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Marc Alan Ostermeier, Chapman M. Wright